Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival

por Maj-Hes, Agnieszka, Szarvas, Tibor, Sevcenco, Sabina, Kramer, Gero
Publicado 2021

Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: Analysis of a medical claims database

por Mohamad Al-Ali, Badereddin, Kramer, Gero, Madersbacher, Stephan, Berger, Ingrid
Publicado 2016

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations

por Reichl, Florian, Muhr, Daniela, Rebhan, Katharina, Kramer, Gero, Shariat, Shahrokh F., Singer, Christian F., Tan, Yen Y.
Publicado 2021

Human Dermis Harbors Distinct Mesenchymal Stromal Cell Subsets

por Vaculik, Christine, Schuster, Christopher, Bauer, Wolfgang, Iram, Nousheen, Pfisterer, Karin, Kramer, Gero, Reinisch, Andreas, Strunk, Dirk, Elbe-Bürger, Adelheid
Publicado 2012

Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment

por Leisser, Asha, Nejabat, Marzieh, Hartenbach, Markus, Agha Mohammadi Sareshgi, Reza, Shariat, Shahrokh, Kramer, Gero, Krainer, Michael, Hacker, Marcus, Haug, Alexander R.
Publicado 2018

Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

por Rasul, Sazan, Hacker, Marcus, Kretschmer-Chott, Elisabeth, Leisser, Asha, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Hartenbach, Markus, Haug, Alexander R.
Publicado 2019

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation

por Hell, Lena, Däullary, Thomas, Burghart, Vanessa, Mauracher, Lisa-Marie, Grilz, Ella, Moser, Bernhard, Kramer, Gero, Schmid, Johannes A., Ay, Cihan, Pabinger, Ingrid, Thaler, Johannes
Publicado 2021

Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

por Vogl, Ursula M, Bojic, Marija, Lamm, Wolfgang, Frischer, Josa M, Pichelmayer, Oskar, Kramer, Gero, Haitel, Andrea, Kitz, Klaus, Harmankaya, Kaan, Zielinski, Christoph C, Schmidinger, Manuela
Publicado 2010

Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

por Rasul, Sazan, Hartenbach, Markus, Wollenweber, Tim, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Pichler, Verena, Vraka, Chrysoula, Hacker, Marcus, Haug, Alexander R.
Publicado 2020

Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical...

por Abufaraj, Mohammad, Grubmüller, Bernhard, Zeitlinger, Markus, Kramer, Gero, Seitz, Christian, Haitel, Andrea, Baltzer, Pascal, Hacker, Marcus, Wadsak, Wolfgang, Pfaff, Sarah, Wiatr, Tomasz, Mitterhauser, Markus, Shariat, Shahrokh F., Hartenbach, Markus
Publicado 2019

Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?

por Huebner, Nicolai Alexander, Korn, Stephan, Resch, Irene, Grubmüller, Bernhard, Gross, Tobias, Gale, Robert, Kramer, Gero, Poetsch, Nina, Clauser, Paola, Haitel, Andrea, Fajkovic, Harun, Shariat, Shahrokh F., Baltzer, Pascal A.
Publicado 2020

Response and Toxicity to the Second Course of 3 Cycles of (177)Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

por Rasul, Sazan, Wollenweber, Tim, Zisser, Lucia, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh F., Eidherr, Harald, Mitterhauser, Markus, Vraka, Chrysoula, Langsteger, Werner, Hacker, Marcus, Haug, Alexander R.
Publicado 2021

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases

por Zisser, Lucia, Yu, Josef, Oszwald, André, Wollenweber, Tim, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh F., Mitterhauser, Markus, Vraka, Chrysoula, Hacker, Marcus, Haug, Alexander R., Rasul, Sazan
Publicado 2022

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis

por Mori, Keiichiro, Mostafaei, Hadi, Sari Motlagh, Reza, Pradere, Benjamin, Quhal, Fahad, Laukhtina, Ekaterina, Schuettfort, Victor M., Kramer, Gero, Abufaraj, Mohammad, Karakiewicz, Pierre I., Kimura, Takahiro, Egawa, Shin, Shariat, Shahrokh F.
Publicado 2021

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

por Wollenweber, Tim, Zisser, Lucia, Kretschmer-Chott, Elisabeth, Weber, Michael, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh F., Mitterhauser, Markus, Schmitl, Stefan, Vraka, Chrysoula, Haug, Alexander R., Hacker, Marcus, Hartenbach, Markus, Rasul, Sazan
Publicado 2021

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

por Grubmüller, Bernhard, Senn, Daniela, Kramer, Gero, Baltzer, Pascal, D’Andrea, David, Grubmüller, Karl Hermann, Mitterhauser, Markus, Eidherr, Harald, Haug, Alexander R., Wadsak, Wolfgang, Pfaff, Sarah, Shariat, Shahrokh F., Hacker, Marcus, Hartenbach, Markus
Publicado 2018

(177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience

por Sartor, Oliver, la Fougère, Christian, Essler, Markus, Ezziddin, Samer, Kramer, Gero, Ellinger, Jörg, Nordquist, Luke, Sylvester, John, Paganelli, Giovanni, Peer, Avivit, Bögemann, Martin, Meltzer, Jeffrey, Sandström, Per, Verholen, Frank, Song, Daniel Y.
Publicado 2022

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

por Chowdhury, Simon, Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique, Feyerabend, Susan, Matveev, Vsevolod, Lefresne, Florence, Lukac, Martin, Wapenaar, Robert, Costa, Luis
Publicado 2020

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate...

por Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique, Feyerabend, Susan, Matveev, Vsevolod, Lefresne, Florence, Lukac, Martin, Wapenaar, Robert, Costa, Luis, Chowdhury, Simon
Publicado 2021

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer

por Csizmarik, Anita, Keresztes, Dávid, Nagy, Nikolett, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Tornyi, Ilona, Lázár, József, Takács, László, Kramer, Gero, Sevcenco, Sabina, Maj‐Hes, Agnieszka, Jurányi, Zsolt, Hadaschik, Boris, Nyirády, Péter, Szarvas, Tibor
Publicado 2022